Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension

NCT00872586 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

304

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Hypertension

Interventions

DRUG: olmesartan medoxomil + hydrochlorothiazide
DRUG: olmesartan medoxomil

Sponsor

Daiichi Sankyo

Collaborators

[object Object]